Abstract

This is a multicenter trial where Herceptin will be administered weekly until disease progression. Gemcitabine will be administered for seven weeks followed by a restaging CT scan of the abdomen on the eighth week. Patients with stable or responding disease will continue on with treatment. Thereafter, patients will receive gemcitabine, once weekly, for three consecutive weeks out of every four week cycle and Herceptin, once weekly, until disease progression. Up to ten patients will be enrolled on this study at the University of Pittsburgh Cancer Institute. Approximately 45 patients will be entered on the study across the United States.
The specific aim of this study is to determine the response rate, toxicities and survival of patients with metastatic pancreatic cancers that overexpress HER-2/neu, after administration of gemcitabine and Herceptin.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000056-41
Application #
6566470
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
41
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Bogen, Debra L; Hanusa, Barbara H; Baker, Robyn et al. (2018) Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study. Hosp Pediatr 8:7-14
Geskin, Larisa J; Akilov, Oleg E; Kwon, Soonyou et al. (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67:423-434
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Cai, HuaLin; Zhou, Xiang; Dougherty, George G et al. (2018) Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia. Psychoneuroendocrinology 90:43-51
Coen, Paul M; Carnero, Elvis A; Goodpaster, Bret H (2018) Exercise and Bariatric Surgery: An Effective Therapeutic Strategy. Exerc Sport Sci Rev 46:262-270
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Chin, Brian; Murphy, Michael L M; Cohen, Sheldon (2018) Age moderates the association between social integration and diurnal cortisol measures. Psychoneuroendocrinology 90:102-109
Hayden, Kathleen M; Baker, Laura D; Bray, George et al. (2018) Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) 10:41-48

Showing the most recent 10 out of 859 publications